Ann E Stapleton

US Patent:

6432681, Aug 13, 2002

Filed:

Jul 9, 1999

Appl. No.:

09/350374

Inventors:

Ann Stapleton - Seattle WA
Edward Nudelman - Seattle WA
Walter E. Stamm - Seattle WA
Sen-Itiroh Hakomori - Mercer Island WA

Assignee:

The Regents of the University of Washington - Seattle WA
The Biomembrane Institute - Seattle WA

International Classification:

C12P 1900

US Classification:

435 74, 435 72

Abstract:

Compositions and methods for diagnosing, treating and preventing recurrent urinary tract infections relate to the detection and use of globosides, such as disialosyl galactosyl-globoside (DSGG) and sialosyl galactosyl-globoside (SGG), and stabilized forms thereof, such as those wherein sialic acid is replaced by KDN.

US Patent:

61302058, Oct 10, 2000

Filed:

Jun 6, 1995

Appl. No.:

8/470045

Inventors:

Ann Stapleton - Seattle WA
Edward Nudelman - Seattle WA
Sen-itiroh Hakomori - Seattle WA
Walter E. Stamm - Seattle WA
Mark Stroud - Seattle WA

Assignee:

The Regents of the University of Washington - Seattle WA
The Biomembrane Institute - Seattle WA

International Classification:

A61K 3170

US Classification:

514 25

Abstract:

A method for determining susceptibility to E. coli urinary tract infection comprising assaying a sample of epithelial cells for the presence or absence of at least one of Le. sup. a, sialosyl galactosyl-globoside, disialosyl galactosyl-globoside and an extended globo structure carrying the same terminal epitopes as Le. sup. a, sialosyl galactosyl-globoside or disialosyl galactosyl-globoside or assaying a sample of vaginal secretions for the presence or absence of at least one of sialosyl galactosyl-globoside or disialosyl galactosyl-globoside, and detecting the presence or absence of the at least one of Le. sup. a, sialosyl galactosyl-globoside, disialosyl galactosyl-globoside and the extended globo structure, as well as a method for diagnosing secretors and nonsecretors of histo-blood group antigens comprising assaying a sample of vaginal epithelial cells, vaginal secretions or buccal epithelial cells for the presence or absence of at least one of sialosyl galactosyl-globoside and disialosyl galactosyl-globoside, and detecting the presence or absence of the at least one of sialosyl galactosyl-globoside and disialosyl galactosyl-globoside, and a method for diagnosing secretors of histo-blood group antigens comprising assaying a sample of vaginal epithelial cells or vaginal secretions for the presence or absence of at least one of globo H, globo ABO and lacto ABO, and detecting for the presence or absence of the at least one of globo H, globo ABO and lacto ABO and, further, a medicament comprising a biologically effective amount of at least one E. coli bacterial receptor analogue, and a pharmaceutically acceptable diluent, carrier or excipient as well as a method for preventing E. coli urinary tract infection comprising administering to a host a biologically effective amount of at least one E.

US Patent:

53745329, Dec 20, 1994

Filed:

Aug 31, 1992

Appl. No.:

7/936400

Inventors:

Ann Stapleton - Seattle WA
Edward Nudelman - Seattle WA
Sen-itiroh Hakomori - Seattle WA
Walter E. Stamm - Seattle WA

Assignee:

The Biomembrane Institute - Seattle WA

International Classification:

G01N 3353
G01N 33566
G01N 33569

US Classification:

435 737

Abstract:

A method for determining susceptibility to E. coli urinary tract infection comprising assaying a sample of epithelial cells for the presence or absence of at least one of sialosyl galactosyl-globoside, disialosyl galactosyl-globoside and an extended globo structure carrying the same terminal epitopes as sialosyl galactosyl-globoside or disialosyl galactosyl-globoside, or assaying a sample of vaginal secretions for the presence or absence of at least one of sialosyl galactosyl-globoside or disialosyl galactosyl-globoside, and detecting the presence or absence of the at least one of sialosyl galactosyl-globoside, disialosyl galactosyl-globoside and the extended globo structure, a medicament comprising a biologically effective amount of at least one E. coli bacterial receptor analogue and a pharmaceutically acceptable diluent, carrier or excipient as well as a method for preventing E. coli urinary tract infection comprising administering to a host a biologically effective amount of at least one E.